Isabel Kalofonos - Jan 10, 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Commercial Officer
Signature
Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Jan 10, 2025
Transactions value $
$0
Form type
4
Date filed
1/13/2025, 04:30 PM
Previous filing
Dec 30, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Award $0 +100K $0.00 100K Jan 10, 2025 Common Stock 100K $40.59 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is exercisable as follows: 25% of the shares subject to the option vest on December 16, 2025, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.